Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States

Abstract

These data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients.

The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View

“…The findings from the Landmark study are echoed in other surveys of PROs in MPN [6,[8][9][10]. In a study conducted in the UK and USA, significant reductions in QoL relative to controls were observed, as well as differences in QoL between UK and US patients, and in symptom burden between male and female patients [6].…”

“…The wide-ranging nature and degree of the impact of MPNs has been highlighted in an increasing number of studies over recent years [3,[6][7][8][9][10][11][12]. One of the largest studies was the international MPN Landmark survey, conducted from April 2016 to October 2016, which included data from over 800 patients with MPN and over 450 physicians across the USA, and almost 700 patients with MPN and over 200 physicians across Australia, Canada, Germany, Italy, Japan, and the UK [3,7].…”

“…The overall burden of disease associated with MPNs has a significant negative impact on patients' lives. Recent studies have shown that MPNs result in marked impairment of quality of life (QoL), work productivity, everyday life, and relationships [3,[6][7][8][9][10], and they are associated with significant emotional issues, including depression and anxiety [11,12]. While the impact is generally greatest in patients with MF, and in higher-risk patients or those with greater symptom burden, negative effects are seen across the disease spectrum [3,6,7,9].…”

<p>Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes</p>

“…Polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by increased red blood cell mass, bone marrow panmyelosis, and Janus kinase 2 (JAK2) mutation 1,2. Constitutional symptoms such as fatigue, weight loss, night sweats and pruritus (so-called “cytokine symptoms”) are present in approximately 61% of patients with PV and affect the quality of life (QoL), overall health and productivity 3–6. Healthcare utilization and costs are also higher in patients with PV than in non-cancer controls 7…”

Polycythämia vera in der differenzialdiagnostischen Abklärung kognitiver Defizite

“…Die Polycythämia vera (Pv) gehört zu den myeloproliferativen Erkrankungen und zeichnet sich primär durch eine Erythrozytose aus. Hierbei zeigen sich vor allem unspezifische Symptome wie Fatigue (73 %) oder Juckreiz (55 %), allerdings können auch neurologische Symptome wie Konzentrationsstörungen (36 %) auftreten [4,5]. In dieser Fallbeschreibung wird als Ursache von kognitiven Defiziten eine Pv beschrieben, bei der eine Verbesserung der Kognition unter entsprechender Therapie zu erreichen war.…”